New score models for predicting bleeding and ischemic of ticagrelor therapy in patients with diabetes mellitus

Abstract

Abstract Purpose Ticagrelor is an antiplatelet drug, and its use increases the risk of bleeding. Coronary artery disease is significantly influenced by the widespread occurrence of diabetes mellitus. In order to decrease the incidence of clinical adverse events, a novel bleeding and thrombosis score is developed in this research. Methods We conducted a retrospective analysis of patient data from two medical centers who were diagnosed with diabetes mellitus and treated with ticagrelor.We gathered information on every patient from the electronic database of the hospital and follow-up.The collected data were statistically analyzed to obtain risk factors for bleeding and ischemic events. Results A total of 851 patients with diabetes mellitus who have been administered ticagrelor are included in our investigation. A total of 76 patients have bleeding events and 80 patients have ischemic events. The analysis of multiple variables indicates that characteristics like the age of > 65, having a previous occurrence of bleeding, experiencing anemia, using aspirin, and taking atorvastatin are linked to a higher likelihood of bleeding. Additionally, the age of > 65, smoking, having a history of blood clots, and having a BMI ≥ 30 are found to increase the risk of ischemia. Conclusion The A4B score has been created by considering five risk factors. The A4B score outperforms the HAS-BLED score(AUC 0.714 vs 0.570).The ABST score has been created by considering four risk factors. The ABST score outperforms the CHA2DS-VASc score(AUC 0.708 vs 0.540). The novel risk-assessment model can potentially detect patients with a substantial likelihood of experiencing bleeding and ischemic events.(2023-09-11,ChiCTR2300075627)